EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling Novel ERCC1–XPF Complex Inhibitors: Bridging the Gap from In Silico Exploration to Experimental Design

Rita Manguinhas iD, Patrícia A Serra iD, Rita B Soares, Rafael Rosell iD, Nuno Gil iD, Nuno G Oliveira, Rita C Guedes iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25021246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Rita Manguinhas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Champalimaud Foundation, Fundação para a Ciência e Tecnologia, Fundação para a Ciência e a Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Modifications in DNA repair pathways are recognized as prognostic markers and potential therapeutic targets in various cancers, including non-small cell lung cancer (NSCLC). Overexpression of ERCC1 correlates with poorer prognosis and response to platinum-based chemotherapy. As a result, there is a pressing need to discover new inhibitors of the ERCC1–XPF complex that can potentiate the efficacy of cisplatin in NSCLC. In this study, we developed a structure-based virtual screening strategy targeting the inhibition of ERCC1 and XPF interaction. Analysis of crystal structures and a library of small molecules known to act against the complex highlighted the pivotal role of Phe293 (ERCC1) in maintaining complex stability. This residue was chosen as the primary binding site for virtual screening. Using an optimized docking protocol, we screened compounds from various databases, ultimately identifying more than one hundred potential inhibitors. Their capability to amplify cisplatin-induced cytotoxicity was assessed in NSCLC H1299 cells, which exhibited the highest ERCC1 expression of all the cell lines tested. Of these, 22 compounds emerged as promising enhancers of cisplatin efficacy. Our results underscore the value of pinpointing crucial molecular characteristics in the pursuit of novel modulators of the ERCC1–XPF interaction, which could be combined with cisplatin to treat NSCLC more effectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansCisplatinDNA RepairResearch DesignDNA-Binding ProteinsEndonucleases

Stichwörter der Autor:innen

DNA repair pathwaysERCC1–XPF complexNSCLCcisplatininhibitorsstructural analysisstructure-based virtual screening

Substanzen

CisplatinDNA-Binding ProteinsEndonucleasesERCC1 protein, human

Autor:innen und Institutionen

  • Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
  • Lung Unit, Champalimaud Clinical Centre (CCC), Champalimaud Foundation, 1400-038 Lisboa, Portugal.
  • Egas Moniz Interdisciplinary Research Center, Instituto Universitário Egas Moniz, 2829-511 Caparica, Portugal.
  • Dr. Rosell Oncology Institute, 08028 Barcelona, Spain.
  • Catalan Institute of Oncology, 08916 Barcelona, Spain.

ORCID-Profile: Rita Manguinhas, Patrícia A Serra, Rafael Rosell, Nuno Gil, Rita C Guedes

Förderung

  • Champalimaud Foundation
  • Fundação para a Ciência e Tecnologia
  • Fundação para a Ciência e a Tecnologia
  • LISBOA-01-0246-FEDER-000017
  • EXPL/QUI-OUT/1288/2021

Zitieren

APA

Manguinhas, R., Serra, P. A., Soares, R. B., Rosell, R., Gil, N., Oliveira, N. G., & Guedes, R. C. (2024). Unveiling Novel ERCC1–XPF Complex Inhibitors: Bridging the Gap from In Silico Exploration to Experimental Design. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25021246

Vancouver

Manguinhas R, Serra PA, Soares RB, Rosell R, Gil N, Oliveira NG, et al. Unveiling Novel ERCC1–XPF Complex Inhibitors: Bridging the Gap from In Silico Exploration to Experimental Design. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25021246

BibTeX
@article{Manguinhas2024,
  author = {Manguinhas, Rita and Serra, Patrícia A and Soares, Rita B and Rosell, Rafael and Gil, Nuno and Oliveira, Nuno G and Guedes, Rita C},
  title = {Unveiling Novel ERCC1–XPF Complex Inhibitors: Bridging the Gap from In Silico Exploration to Experimental Design},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25021246}
}
Kostenlos starten →